Advanced Biomed (ADVB) Cash & Equivalents (2023 - 2026)

Advanced Biomed (ADVB) has 4 years of Cash & Equivalents data on file, last reported at $2.6 million in Q1 2026.

• Quarterly Cash & Equivalents fell 18.06% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (down 18.06% YoY) and the FY2025 annual result came in at $2.9 million, up 11.35% from the prior year.
• Cash & Equivalents was little changed at $2.6 million in Q1 2026 per ADVB's latest filing, from $2.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $3.2 million in Q1 2025, with the low at $2.6 million in Q1 2026.
• Average Cash & Equivalents over 4 years is $2.7 million, with a median of $2.7 million recorded in 2024.
• Year-over-year, Cash & Equivalents advanced 19.25% in 2025 and declined 18.06% in 2026.
• Advanced Biomed's Cash & Equivalents stood at $2.8 million in 2023, then fell by 4.64% to $2.6 million in 2024, then retreated by 1.62% to $2.6 million in 2025, then fell by 0.08% to $2.6 million in 2026.
• Business Quant data shows ADVB's Cash & Equivalents at $2.6 million in Q1 2026, $2.6 million in Q4 2025, and $2.7 million in Q3 2025.